BOEHRINGER-INGELHEIM
Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023
The Top Employers Institute awarded Boehringer Ingelheim for the third year in succession a “Global Top Employer”, one of the world’s 15 best employers. The certification also highlights the company’s commitment to prioritizing mental health for employees.
Boehringer Ingelheim’s employer offerings do particularly stand out in the dimensions of wellbeing, work environment, as well as rewards and recognition. The results reflect the company’s holistic employee healthcare and wellbeing approach that, beyond its emphasis on mental health, integrates concepts of physical, social and financial health. Through dedicated programs and offers, its employees receive support that is relevant for them and their families. This includes a work environment of physical and emotional security, an inclusive way of working together creating a sense of belonging, mental health awareness initiatives and manager trainings, in-house psychologists and counsellors, focus on work-life-balance, opportunities for volunteering, and competitive pay and benefits.
“People are at the core of everything that our company does. The strong human dimension of our corporate culture implies a commitment to our people as individuals, not just as professionals. The Global Top Employers award acknowledges that,” says Dr Sven Sommerlatte, Global Head of Human Resources at Boehringer Ingelheim. “By prioritizing our employees’ mental health, we want to ensure that our colleagues feel empowered to ask for help and be able to rely on each other’s support when in need.”
Mental disorders affect one in eight people worldwide and mental health conditions can substantially impact all areas of life, including relationships with family and friends, the ability to participate in the community or work performance.1 While the need to take good care of physical health is well established, the awareness and means for taking appropriate care of mental health still receives significantly less attention. Boehringer Ingelheim strives to curb the stigma often experienced by people with mental health conditions as an employer and beyond. The research-driven company has a longstanding commitment to mental health research that could offer a more targeted approach to addressing and treating the underlying brain biology, also known as precision psychiatry.
Boehringer Ingelheim has been listed among the top employers in multiple countries and regions for the past nine years. This year, Boehringer Ingelheim will receive the award in 29 countries, as well as additional certifications in Europe, the Asia Pacific, and – ranked first – the Latin America regions.
Please click on the following link for ‘Notes to Editors’ and ‘References’:
https://www.boehringer-ingelheim.com/about-us/corporate-profile/global-top-employer-2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005538/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PLANETS27.1.2023 18:01:35 CET | Press release
More Than Half of Visitors to teamLab Planets in Toyosu, Tokyo Now Come From Overseas. Starting in March, Artworks Featuring Cherry Blossoms That Bloom Across the Space Will Be on View for the Spring Season Only
GPS27.1.2023 11:13:16 CET | Press release
Global Processing Services Appoints Former Visa Executive Jim McCarthy to Lead Global Sales and Product
ARCTIC-MINERAL-RESOURCES27.1.2023 11:13:06 CET | Press release
Major Landowner Federations to Support AMR Against Nordic Mining ASA (NOM) in the Norwegian Supreme Court
MA-BOSTON-METAL27.1.2023 11:12:53 CET | Press release
Green Steel Technology Company Boston Metal Announces $120M Series C Financing Led by ArcelorMittal
IPSEN27.1.2023 11:12:43 CET | Press release
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom